Structure Therapeutics (GPCR) Accumulated Expenses (2022 - 2026)

Structure Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $46.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 83.96% year-over-year to $46.6 million; the TTM figure through Mar 2026 stood at $46.6 million (up 83.96% YoY), while the FY2025 annual figure was $12.4 million, up 77.0% from the prior year.
• Accumulated Expenses was $46.6 million for Q1 2026 at Structure Therapeutics, up from $12.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $46.6 million in Q1 2026 to a low of $1.1 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $14.3 million across 5 years, with a median of $8.1 million in 2023.
• Biggest YoY gain for Accumulated Expenses was 1137.46% in 2025; the steepest drop was 70.3% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $6.7 million in 2022, then surged by 175.3% to $18.6 million in 2023, then sank by 62.15% to $7.0 million in 2024, then surged by 77.0% to $12.4 million in 2025, then soared by 274.4% to $46.6 million in 2026.
• The last three Accumulated Expenses figures came in at $46.6 million (Q1 2026), $12.4 million (Q4 2025), and $36.9 million (Q3 2025), per Business Quant data.